代谢途径基于对的签名作为阿尔茨海默病患者潜在的非侵入性诊断标记物
Yunwen Feng1, Xingyu Chen1, Xiaohua Douglas Zhang2
1Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Taipa, Macao SAR 999078, China.
Genes
|June 28, 2023
概括
这项研究开发了一种新的基于血液的评分系统,使用代谢途径签名来诊断阿尔茨海默病 (AD). 该系统准确地区分了AD患者,为早期检测和了解疾病机制提供了有前途的工具.
科学领域:
- 生物化学 生物化学
- 基因组学就是基因组学.
- 神经科学是一个神经科学.
背景情况:
- 阿尔茨海默病 (AD) 是一种无法治愈的神经退行性疾病.
- 早期诊断和了解AD的分子机制对于有效的管理至关重要.
- 代谢功能障碍越来越被认为是AD病变的关键因素.
研究的目的:
- 建立基于血液代谢特征的阿尔茨海默病诊断模型.
- 调查将代谢功能障碍与AD联系起来的分子机制.
- 根据代谢和免疫特征,将AD患者分为不同的亚组.
主要方法:
- 构建代谢途径双向 (MPP) 签名以分析途径相互作用.
- 生物信息分析包括差异表达,功能丰富和网络分析.
- 非负矩阵因子化 (NMF) 用于无监督的集群和多机器学习方法用于代谢途径对对计分系统 (MPPSS).
主要成果:
- 确定与AD相关的关键代谢途径,如氧化酸化和脂肪酸生物合成.
- 将AD患者分为两小组 (S1,S2),具有不同的代谢和免疫活动,表明S2患有更严重的疾病.
- 开发的MPPSS在区分AD患者方面取得了很高的准确性,在验证数据集中AUC高达0.99.
结论:
- 一个新的,基于代谢的评分系统 (MPPSS) 用于阿尔茨海默病的诊断使用血液转录组数据已经成功开发.
- 这项研究为代谢功能障碍的作用及其与AD免疫反应的相互作用提供了新的见解.
- 这些发现支持血液代谢特征的潜力,用于非侵入性AD查和个性化的患者分层.
更多相关视频
相关概念视频
Alzheimer's Disease: Overview
530
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
530
Alzheimer's Disease: Treatment
222
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
222


